

Charles S Fuchs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7938953/publications.pdf>

Version: 2024-02-01

250
papers

26,988
citations

9786

73
h-index

6654

156
g-index

254
all docs

254
docs citations

254
times ranked

31458
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	5.3	72
2	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
3	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	1.6	20
4	Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study. <i>Cancer Prevention Research</i> , 2022, 15, 265-272.	1.5	7
5	Coffee Intake of Colorectal Cancer Patients and Prognosis According to Histopathologic Lymphocytic Reaction and T-Cell Infiltrates. <i>Mayo Clinic Proceedings</i> , 2022, 97, 124-133.	3.0	3
6	Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). <i>Oncologist</i> , 2022, 27, e494-e505.	3.7	5
7	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298.	3.7	2
8	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479.	1.0	3
9	Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 101-101.	1.6	0
10	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. <i>JAMA Network Open</i> , 2022, 5, e220145.	5.9	3
11	Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	7
12	Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 215-227.	3.4	23
13	Myths about diversity in clinical trials reduce return on investment for industry. <i>Nature Medicine</i> , 2022, 28, 1520-1522.	30.7	6
14	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	7.0	35
15	No Association Between Vitamin D Supplementation and Risk of Colorectal Adenomas or Serrated Polyps in a Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 128-135.e6.	4.4	28
16	Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa089.	2.9	11
17	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	2.9	6
18	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501.	2.4	117

#	ARTICLE	IF	CITATIONS
19	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1069-1081.	7.0	75
20	Unrestrained eating behavior and risk of digestive system cancers: a prospective cohort study. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1612-1624.	4.7	9
21	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	7.0	53
22	Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 757-764.	2.5	6
23	Dairy consumption, plasma metabolites, and risk of type 2 diabetes. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 163-174.	4.7	29
24	Prediagnostic Inflammation and Pancreatic Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1186-1193.	6.3	9
25	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1277.	7.4	63
26	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab034.	2.9	4
27	Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3568-3568.	1.6	0
28	Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3588-3588.	1.6	0
29	Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. <i>JAMA Network Open</i> , 2021, 4, e2112539.	5.9	48
30	Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 215-220.	1.5	2
31	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	7.1	184
32	Discovery and Features of an Alkylating Signature in Colorectal Cancer. <i>Cancer Discovery</i> , 2021, 11, 2446-2455.	9.4	42
33	Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. <i>Cancer Research</i> , 2021, 81, CT167-CT167.	0.9	11
34	Simple Sugar and Sugar-Sweetened Beverage Intake During Adolescence and Risk of Colorectal Cancer Precursors. <i>Gastroenterology</i> , 2021, 161, 128-142.e20.	1.3	58
35	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1408-1417.	4.7	9
36	Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	5.3	7
38	KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 2847-2855.	2.4	33
39	Unrestrained eating behavior and risk of mortality: A prospective cohort study. <i>Clinical Nutrition</i> , 2021, 40, 5419-5429.	5.0	5
40	Total Vitamin D Intake and Risks of Early-Onset Colorectal Cancer and Precursors. <i>Gastroenterology</i> , 2021, 161, 1208-1217.e9.	1.3	40
41	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	1.6	0
42	Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. <i>JAMA Network Open</i> , 2021, 4, e2139593.	5.9	55
43	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	2.9	22
44	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1003-1012.	6.3	59
45	Endogenous sex hormones and colorectal cancer survival among men and women. <i>International Journal of Cancer</i> , 2020, 147, 920-930.	5.1	17
46	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	2.9	8
47	Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. <i>EBioMedicine</i> , 2020, 57, 102860.	6.1	31
48	Diabetes, Weight Change, and Pancreatic Cancer Risk. <i>JAMA Oncology</i> , 2020, 6, e202948.	7.1	72
49	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	7.1	611
50	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	7.1	24
51	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2020, 13, 1055-1062.	1.5	17
52	Post-diagnosis dietary insulinemic potential and survival outcomes among colorectal cancer patients. <i>BMC Cancer</i> , 2020, 20, 817.	2.6	16
53	Prediagnostic Circulating Concentrations of Vitamin D Binding Protein and Survival among Patients with Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2323-2331.	2.5	9
54	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. <i>JAMA Network Open</i> , 2020, 3, e2023500.	5.9	8

#	ARTICLE	IF	CITATIONS
55	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 999-1008.	2.5	19
56	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1586-1595.	2.5	8
57	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1692-1695.	2.5	5
58	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz096.	2.9	14
59	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , 2020, 181, 832-847.e18.	28.9	77
60	Dietary Intake of Branched-Chain Amino Acids and Risk of Colorectal Cancer. <i>Cancer Prevention Research</i> , 2020, 13, 65-72.	1.5	12
61	Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3089-3089.	1.6	3
62	Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4003-4003.	1.6	2
63	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1â€“positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4503-4503.	1.6	31
64	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4512-4512.	1.6	26
65	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4537-4537.	1.6	38
66	Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1â€“positive (CPS â‰¥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 427-427.	1.6	13
67	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 430-430.	1.6	20
68	How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 89-89.	1.6	1
69	A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS460-TPS460.	1.6	3
70	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS463-TPS463.	1.6	4
71	Long-term cancer survival in cohorts of U.S. health professionals.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12075-12075.	1.6	0
72	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 146-157.	6.3	129

#	ARTICLE	IF	CITATIONS
73	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). Journal of the National Cancer Institute, 2019, 111, 170-179.	6.3	19
74	Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Investigational New Drugs, 2019, 37, 159-165.	2.6	28
75	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of Clinical Oncology, 2019, 37, 2620-2631.	1.6	51
76	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVPF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	10.7	193
77	Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women. Journal of Nutrition, 2019, 149, 1215-1221.	2.9	11
78	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clinical Cancer Research, 2019, 25, 7497-7505.	7.0	44
79	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	10.7	191
80	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research, 2019, 25, 5202-5211.	7.0	26
81	Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses' Health Study II. British Journal of Cancer, 2019, 121, 86-94.	6.4	19
82	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes and Control, 2019, 30, 757-765.	1.8	4
83	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. European Journal of Cancer, 2019, 111, 82-93.	2.8	17
84	FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer, 2019, 125, 2213-2221.	4.1	14
85	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer, 2019, 22, 828-837.	5.3	181
86	Calcium Intake and Risk of Colorectal Cancer According to Tumor-infiltrating T Cells. Cancer Prevention Research, 2019, 12, 283-294.	1.5	11
87	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncology, 2019, 15, 943-952.	2.4	133
88	Fish and marine fatty acids intakes, the FADS genotypes and long-term weight gain: a prospective cohort study. BMJ Open, 2019, 9, e022877.	1.9	5
89	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology, 2019, 20, 1494-1505.	14.5	83
90	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	6.3	21

#	ARTICLE	IF	CITATIONS
91	Calcium Intake and Survival after Colorectal Cancer Diagnosis. <i>Clinical Cancer Research</i> , 2019, 25, 1980-1988.	7.0	20
92	Inherited DNA-Repair Defects in Colorectal Cancer. <i>American Journal of Human Genetics</i> , 2018, 102, 401-414.	6.2	89
93	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 730-749.	9.4	367
94	Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1300-1306.e3.	4.4	21
95	Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. <i>International Journal of Cancer</i> , 2018, 143, 1047-1053.	5.1	22
96	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. <i>JAMA Oncology</i> , 2018, 4, 783.	7.1	147
97	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	12.8	188
98	Marine ω -3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 438-445.	2.5	52
99	Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality. <i>Gastroenterology</i> , 2018, 154, 916-926.e9.	1.3	52
100	Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain <i>Fusobacterium nucleatum</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1622-1631.e3.	4.4	103
101	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	7.1	1,350
102	Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). <i>Gut</i> , 2018, 67, 1475-1483.	12.1	39
103	Social integration and survival after diagnosis of colorectal cancer. <i>Cancer</i> , 2018, 124, 833-840.	4.1	29
104	Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. <i>Journal of Oncology Practice</i> , 2018, 14, e823-e833.	2.5	11
105	Reply to L. Fornaro et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 1179-1180.	1.6	0
106	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018, 36, 1112-1120.	1.6	50
107	Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. <i>Genome Biology</i> , 2018, 19, 142.	8.8	20
108	The Amount of <i>Bifidobacterium</i> Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. <i>American Journal of Pathology</i> , 2018, 188, 2839-2852.	3.8	51

#	ARTICLE	IF	CITATIONS
109	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2018, 2, pky017.	2.9	10
110	Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. European Journal of Cancer, 2018, 103, 98-107.	2.8	21
111	Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS ONE, 2018, 13, e0199244.	2.5	25
112	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	13.7	984
113	Association of dietary insulinemic potential and colorectal cancer risk in men and women. American Journal of Clinical Nutrition, 2018, 108, 363-370.	4.7	57
114	KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis.. Journal of Clinical Oncology, 2018, 36, 723-723.	1.6	1
115	Body Mass Index and Other Anthropomorphic Variables in Relation to Risk of Colorectal Carcinoma Subtypes Classified by Tumor Differentiation Status. FASEB Journal, 2018, 32, 677.9.	0.5	0
116	Tumor Nuclear <i>YAP1</i> Expression Status and Molecular Characteristics in relation to Immune Response to Colorectal Carcinoma. FASEB Journal, 2018, 32, 406.5.	0.5	0
117	Multiplexed Immuno-profiling of the Colorectal Carcinoma Microenvironment Using Archival Human Tissue. FASEB Journal, 2018, 32, 818.4.	0.5	0
118	Bifidobacterium Genus in Colorectal Carcinoma Tissue in relation to Tumor Characteristics and Patient Survival. FASEB Journal, 2018, 32, 407.3.	0.5	0
119	Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.. Journal of Clinical Oncology, 2018, 36, 4044-4044.	1.6	1
120	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 1086-1095.	1.6	383
121	A Prospective Study of Smoking and Risk of Synchronous Colorectal Cancers. American Journal of Gastroenterology, 2017, 112, 493-501.	0.4	17
122	Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. International Journal of Cancer, 2017, 140, 2648-2656.	5.1	17
123	Marine ω -3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. Gut, 2017, 66, 1790-1796.	12.1	89
124	Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes. Gastroenterology, 2017, 152, 1944-1953.e1.	1.3	124
125	Leucocyte telomere length, genetic variants at the <i>TERT</i> gene region and risk of pancreatic cancer. Gut, 2017, 66, 1116-1122.	12.1	39
126	Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. Oncoimmunology, 2017, 6, e1284720.	4.6	18

#	ARTICLE	IF	CITATIONS
127	Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies. <i>European Journal of Epidemiology</i> , 2017, 32, 419-430.	5.7	17
128	Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor. <i>Gastroenterology</i> , 2017, 153, 1517-1530.e14.	1.3	62
129	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017, 358, 1443-1448.	12.6	983
130	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222.	7.0	44
131	A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. <i>Oncologist</i> , 2017, 22, 107-114.	3.7	18
132	Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by <i>Fusobacterium nucleatum</i> in Tumor Tissue. <i>JAMA Oncology</i> , 2017, 3, 921.	7.1	243
133	Development and Validation of the PREMM ₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 2165-2172.	1.6	126
134	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3671-3677.	1.6	112
135	Cigarette Smoking and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2017, 35, 1822-1828.	1.6	78
136	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.6	110
137	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	1.6	37
138	Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10059-10059.	1.6	1
139	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4003.	1.6	134
140	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4046-4046.	1.6	14
141	Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15000-e15000.	1.6	0
142	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. <i>Oncotarget</i> , 2016, 7, 66328-66343.	1.8	88
143	Plasma 25-Hydroxyvitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer in the Nurses' Health Study. <i>Cancer Prevention Research</i> , 2016, 9, 664-672.	1.5	38
144	Development and Validation of an Empirical Dietary Inflammatory Index. <i>Journal of Nutrition</i> , 2016, 146, 1560-1570.	2.9	263

#	ARTICLE	IF	CITATIONS
145	Development and validation of empirical indices to assess the insulinaemic potential of diet and lifestyle. British Journal of Nutrition, 2016, 116, 1787-1798.	2.3	91
146	Association of Physical Activity by Type and Intensity With Digestive System Cancer Risk. JAMA Oncology, 2016, 2, 1146.	7.1	78
147	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1185-1191.	2.5	29
148	Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. British Journal of Cancer, 2016, 114, 995-1002.	6.4	31
149	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports, 2016, 15, 857-865.	6.4	671
150	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. British Journal of Cancer, 2016, 115, 974-982.	6.4	53
151	Associations between nut consumption and inflammatory biomarkers,. American Journal of Clinical Nutrition, 2016, 104, 722-728.	4.7	80
152	Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study. International Journal of Cancer, 2016, 139, 1949-1957.	5.1	33
153	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Research, 2016, 76, 7160-7167.	0.9	46
154	Nut consumption and prostate cancer risk and mortality. British Journal of Cancer, 2016, 115, 371-374.	6.4	24
155	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Journal of Clinical Oncology, 2016, 34, 2899-2905.	1.6	49
156	Sedentary behaviors and light-intensity activities in relation to colorectal cancer risk. International Journal of Cancer, 2016, 138, 2109-2117.	5.1	23
157	CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. British Journal of Cancer, 2016, 114, 221-229.	6.4	18
158	Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women. Cancer Prevention Research, 2016, 9, 27-34.	1.5	30
159	Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 497-504.	3.8	156
160	Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nature Genetics, 2016, 48, 189-194.	21.4	211
161	Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis. Carcinogenesis, 2016, 37, 87-95.	2.8	62
162	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. Journal of the National Cancer Institute, 2016, 108, djv363.	6.3	37

#	ARTICLE	IF	CITATIONS
163	Long-term status and change of body fat distribution, and risk of colorectal cancer: a prospective cohort study. <i>International Journal of Epidemiology</i> , 2016, 45, 871-883.	1.9	52
164	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	1.6	116
165	Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1489-1498.	7.0	9
166	Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naïve metastatic esophagogastric adenocarcinoma (MEGA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4-4.	1.6	17
167	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS178-TPS178.	1.6	2
168	Novel driver genes and genomic predictors of immune infiltrates in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-557.	1.6	0
169	Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months. <i>Scientific Reports</i> , 2015, 5, 10411.	3.3	7
170	Reduction of parathyroid hormone with vitamin D supplementation in blacks: a randomized controlled trial. <i>BMC Nutrition</i> , 2015, 1, .	1.6	3
171	<sc><i>TERT</i></sc> gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2015, 137, 2175-2183.	5.1	57
172	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	6.3	152
173	Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. <i>Gastroenterology</i> , 2015, 149, 614-622.	1.3	44
174	<i>Fusobacterium nucleatum</i> and T Cells in Colorectal Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 653.	7.1	498
175	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. <i>American Journal of Human Genetics</i> , 2015, 96, 487-497.	6.2	101
176	LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. <i>Genes and Development</i> , 2015, 29, 1074-1086.	5.9	92
177	Response. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv150-djv150.	6.3	0
178	Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus. <i>Journal of Clinical Oncology</i> , 2015, 33, 29-35.	1.6	83
179	Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. <i>Modern Pathology</i> , 2015, 28, 14-29.	5.5	172
180	Red Meat Intake, NAT2, and Risk of Colorectal Cancer: A Pooled Analysis of 11 Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 198-205.	2.5	38

#	ARTICLE	IF	CITATIONS
181	Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1398-1406.	2.5	47
182	Genome-wide association study of colorectal cancer identifies six new susceptibility loci. <i>Nature Communications</i> , 2015, 6, 7138.	12.8	138
183	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2015, 47, 911-916.	21.4	224
184	Adulthood Weight Change and Risk of Colorectal Cancer in the Nurses' Health Study and Health Professionals Follow-up Study. <i>Cancer Prevention Research</i> , 2015, 8, 620-627.	1.5	31
185	Early Life Body Fatness and Risk of Colorectal Cancer in U.S. Women and Men—Results from Two Large Cohort Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 690-697.	2.5	74
186	Marine ω -3 Polyunsaturated Fatty Acids and Risk for Colorectal Cancer According to Microsatellite Instability. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	37
187	Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1133.	7.4	171
188	Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. <i>Carcinogenesis</i> , 2015, 36, 999-1007.	2.8	28
189	Oral Contraceptive Use and Colorectal Cancer in the Nurses' Health Study I and II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1214-1221.	2.5	16
190	Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. <i>Cancer Prevention Research</i> , 2015, 8, 1138-1145.	1.5	23
191	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3598-3607.	1.6	60
192	Anorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation Therapy. <i>Radiographics</i> , 2015, 35, 2090-2107.	3.3	42
193	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 345.	6.3	115
194	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	1.6	87
195	Joint Effects of Colorectal Cancer Susceptibility Loci, Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e92212.	2.5	12
196	Post Diagnosis Diet Quality and Colorectal Cancer Survival in Women. <i>PLoS ONE</i> , 2014, 9, e115377.	2.5	74
197	Predicted 25(OH)D Score and Colorectal Cancer Risk According to Vitamin D Receptor Expression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1628-1637.	2.5	23
198	Gene-Environment Interaction Involving Recently Identified Colorectal Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1824-1833.	2.5	48

#	ARTICLE	IF	CITATIONS
199	Null Association between Vitamin D and PSA Levels among Black Men in a Vitamin D Supplementation Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1944-1947.	2.5	22
200	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2014, 19, 637-638.	3.7	292
201	Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women. <i>International Journal of Cancer</i> , 2014, 134, 2458-2467.	5.1	46
202	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	2.9	90
203	Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 1479-1488.	4.7	27
204	Response. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju181-dju181.	6.3	0
205	Urinary PGE-M Levels Are Associated with Risk of Colorectal Adenomas and Chemopreventive Response to Anti-Inflammatory Drugs. <i>Cancer Prevention Research</i> , 2014, 7, 758-765.	1.5	36
206	Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer Prognosis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	58
207	Plasma 25-Hydroxyvitamin D and Risk of Colorectal Cancer after Adjusting for Inflammatory Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2175-2180.	2.5	16
208	Risk of Hypercalcemia in Blacks Taking Hydrochlorothiazide and Vitamin D. <i>American Journal of Medicine</i> , 2014, 127, 772-778.	1.5	10
209	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2014, 383, 31-39.	13.7	1,833
210	RNF43 is frequently mutated in colorectal and endometrial cancers. <i>Nature Genetics</i> , 2014, 46, 1264-1266.	21.4	388
211	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28
212	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	21.4	294
213	Progress and Opportunities in Molecular Pathological Epidemiology of Colorectal Premalignant Lesions. <i>American Journal of Gastroenterology</i> , 2014, 109, 1205-1214.	0.4	55
214	Sleep Duration Affects Risk for Ulcerative Colitis: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1879-1886.	4.4	76
215	Aspirin, the new targeted therapy in colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 186-9.	0.3	0
216	Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2563.	7.4	146

#	ARTICLE	IF	CITATIONS
217	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013, 12, 233-238.	2.3	31
218	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	2.3	17
219	A Prospective Study of Duration of Smoking Cessation and Colorectal Cancer Risk by Epigenetics-related Tumor Classification. <i>American Journal of Epidemiology</i> , 2013, 178, 84-100.	3.4	81
220	Physical Activity, Tumor PTGS2 Expression, and Survival in Patients with Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1142-1152.	2.5	34
221	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1702-1711.	6.3	163
222	The Joint Association of Eating Frequency and Diet Quality With Colorectal Cancer Risk in the Health Professionals Follow-up Study. <i>American Journal of Epidemiology</i> , 2012, 175, 664-672.	3.4	14
223	Hormone Therapy Increases Risk of Ulcerative Colitis but not Crohn's Disease. <i>Gastroenterology</i> , 2012, 143, 1199-1206.	1.3	101
224	Reported behavior of eating anything at anytime and risk of colorectal cancer in women. <i>International Journal of Cancer</i> , 2012, 130, 1395-1400.	5.1	4
225	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011, 43, 964-968.	21.4	270
226	Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. <i>Gut</i> , 2011, 60, 397-411.	12.1	453
227	A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. <i>Nature Genetics</i> , 2010, 42, 224-228.	21.4	539
228	Aspirin Use and Survival After Diagnosis of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 649.	7.4	497
229	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 176-185.	1.6	208
230	Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2009, 41, 986-990.	21.4	597
231	Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803. <i>Journal of Clinical Oncology</i> , 2008, 26, 4109-4115.	1.6	245
232	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. <i>Clinical Cancer Research</i> , 2008, 14, 8263-8269.	7.0	52
233	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 754.	7.4	369
234	Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. <i>New England Journal of Medicine</i> , 2007, 356, 2131-2142.	27.0	692

#	ARTICLE	IF	CITATIONS
235	IGFBP3 Promoter Methylation in Colorectal Cancer: Relationship with Microsatellite Instability, CpG Island Methylator Phenotype, p53. Neoplasia, 2007, 9, 1091-1098.	5.3	34
236	Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample. Journal of Molecular Diagnostics, 2007, 9, 305-314.	2.8	296
237	Precision and Performance Characteristics of Bisulfite Conversion and Real-Time PCR (MethyLight) for Quantitative DNA Methylation Analysis. Journal of Molecular Diagnostics, 2006, 8, 209-217.	2.8	361
238	Physical Activity and Survival After Colorectal Cancer Diagnosis. Journal of Clinical Oncology, 2006, 24, 3527-3534.	1.6	762
239	Irinotecan in the treatment of colorectal cancer. Cancer Treatment Reviews, 2006, 32, 491-503.	7.7	148
240	Cancer of the Appendix. , 2006, , 410-417.		0
241	Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. Journal of Clinical Oncology, 2006, 24, 3535-3541.	1.6	664
242	Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men. Journal of the National Cancer Institute, 2006, 98, 451-459.	6.3	922
243	Dietary Patterns and Pancreatic Cancer Risk in Men and Women. Journal of the National Cancer Institute, 2005, 97, 518-524.	6.3	95
244	Assessment of a Dietary Questionnaire in Cancer Patients Receiving Cytotoxic Chemotherapy. Journal of Clinical Oncology, 2005, 23, 8453-8460.	1.6	23
245	Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing. Journal of Molecular Diagnostics, 2005, 7, 413-421.	2.8	448
246	Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 138-47.	2.5	52
247	Aspirin Use and Risk for Colorectal Adenoma. Annals of Internal Medicine, 2004, 141, 406.	3.9	0
248	Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer, 2003, 98, 484-495.	4.1	285
249	A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 2002, 94, 3186-3191.	4.1	95
250	Prospective Study of Fruit and Vegetable Consumption and Incidence of Colon and Rectal Cancers. Journal of the National Cancer Institute, 2000, 92, 1740-1752.	6.3	369